Difference between revisions of "CT Angiography Biomarker Ctte"

From QIBA Wiki
Jump to navigation Jump to search
(45 intermediate revisions by 2 users not shown)
Line 1: Line 1:
 
'''Co-chairs''': Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT
 
'''Co-chairs''': Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT
'''Secretary''': Julie Lisiecki
+
'''RSNA Staff Support''': Julie Lisiecki
 
* [http://tinyurl.com/QIBA-CT-Angiography-Roster Roster]
 
* [http://tinyurl.com/QIBA-CT-Angiography-Roster Roster]
 +
  
 
==Meetings==
 
==Meetings==
  
 
'''Recent Call Summaries:'''
 
'''Recent Call Summaries:'''
*[[Media: 2018 08 27 QIBA CT Angiography_FINAL.pdf | August 27, 2018]]
+
 
*[[Media: 2018 08 13 QIBA CT Angiography_FINAL.pdf | August 13, 2018]]
+
*[[Media: 2019 09 09 QIBA CT Angiography_FINAL.pdf | September 9, 2019]]
*[[Media: 2018 07 30 QIBA CT Angiography_FINAL.pdf | July 30, 2018]]
+
*[[Media: 2019 08 26 QIBA CT Angiography_FINAL.pdf | August 26, 2019]]
 +
*[[Media: 2019 08 12 QIBA CT Angiography_FINAL.pdf | August 12, 2019]]
 +
*[[Media: 2019 07 29 QIBA CT Angiography_FINAL.pdf | July 29, 2019]]
 +
* Hiatus for public comment period (April - July)
 +
*[[Media: 2019 04 08 QIBA CT Angiography_FINAL-b.pdf | April 8, 2019]]
 +
*[[Media: 2019 03 11 QIBA CT Angiography_FINAL-b.pdf | March 11, 2019]]
 +
*[[Media: 2019 02 25 QIBA CT Angiography_FINAL.pdf | February 25, 2019]]
  
 
'''''[[CT Angiography Call Summaries Archive]]'''''
 
'''''[[CT Angiography Call Summaries Archive]]'''''
Line 17: Line 24:
 
Excerpt from the biomarker committee submission form:
 
Excerpt from the biomarker committee submission form:
  
The proposed QIBA Atherosclerosis Biomarkers Committee (ABC) will be composed of members from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Furthermore, stakeholders from different manufacturers will be included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee will develop technical performance standards to serve as atherosclerosis compositional biomarkers. Moreover, we will involve stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.
+
The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA).  The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.
  
 
==Profile Development==
 
==Profile Development==
*[[Media:QIBA_Atherosclerosis Biomarkers Profile 2018-08-15.docx | QIBA Atherosclerosis Biomarkers Profile 2018-08-15]]
+
 
 +
 
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-09-09b.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | September 9, 2019]]
 +
*[[Media:CTA Comments 2019-09-09.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | September 9, 2019]]
 +
 
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-08-26.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | August 26, 2019]]
 +
*[[Media:CTA Comments 2019-08-26.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | August 26, 2019]]
 +
 
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-08-12.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | August 12, 2019]]
 +
*[[Media:CTA Comments 2019-08-12.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | August 12, 2019]]
 +
 
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-07-29.PDF | QIBA Atherosclerosis Biomarkers Profile Draft | July 29, 2019]]
 +
*[[Media:CTA Comments 2019-07-29.xlsx | QIBA Atherosclerosis Biomarkers Profile Comments Spreadsheet | July 29, 2019]]
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-02-26.docx | QIBA Atherosclerosis Biomarkers Profile Draft | February 26, 2019]]
 +
*[[Media:Atherosclerosis_Biomarkers_Profile_2019-02-11.docx | QIBA Atherosclerosis Biomarkers Profile Draft | February 11, 2019]]
 +
*[[Media:2019_01-31_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | January 31, 2019]]
 +
*[[Media:2019_01-14_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | January 14, 2019]]
 +
*[[Media:2018_12-17_Atherosclerosis_Biomarkers_Profile-DRAFT.docx | QIBA Atherosclerosis Biomarkers Profile Draft | December 17, 2018]]
 +
 
 +
'''''[[Atherosclerosis Biomarkers Profile Draft Archive]]'''''
  
 
==Groundwork Projects==
 
==Groundwork Projects==
 
  
 
==Reference Materials==
 
==Reference Materials==

Revision as of 20:36, 9 September 2019

Co-chairs: Andrew Buckler, MS; Luca Saba, MD; Uwe Joseph Schoepf, MD, FAHA, FSCBT-MR, FNASCI, FSCCT RSNA Staff Support: Julie Lisiecki


Meetings

Recent Call Summaries:

CT Angiography Call Summaries Archive

Project Snapshot - CT Angiography

The group intends to pursue writing quantitative profiles for both Coronary computed tomography angiography (CCTA) and CT angiography (CTA).

Excerpt from the biomarker committee submission form:

The QIBA Atherosclerosis Biomarkers Committee (ABC) is organized to document quantitative profiles for both Computed Tomography Angiography (CTA) and Coronary CTA (CCTA). The membership is composed of participants from multiple centers of excellence within North America and Europe utilizing different CTA vendors, acquisitions and scanner types, and analysis software vendors. Representatives from different manufacturers are included in the committee, who are interested in working closely with the committee in optimizing imaging biomarkers for scientific trials and clinical routine use. The Biomarker Committee develops technical performance standards to serve as atherosclerosis compositional biomarkers, engaging stakeholders from different societies, in addition to the RSNA, for example ASNR, SCCT, ACR, etc.

Profile Development

Atherosclerosis Biomarkers Profile Draft Archive

Groundwork Projects

Reference Materials

Conformance Materials